HAIC单治疗HAIC联合治疗 HAIC前瞻性临川实验潜在障碍
返回首页

基于HAIC的联合治疗

时间:2021-12-24 23:25来源:www.ynjr.net 作者:杨宁介入医学网
The following characteristics of HAIC render it a suitable candidate for combination with other antineoplastic agents for advanced HCC: it is associated with fewer systemic adverse events compared with intravenous chemotherapy, and its cyt
        The following characteristics of HAIC render it a suitable candidate for combination with other antineoplastic agents for advanced HCC: it is associated with fewer systemic adverse events compared with intravenous chemotherapy, and its cytotoxic mechanism is distinct from those of other HCC therapeutic modalities.、、
 
HAIC的以下特点使其成为与其他抗肿瘤药物联合治疗晚期HCC的合适候选药物:与静脉化疗相比,它与更少的全身性不良事件相关,其细胞毒性机制不同于其他HCC治疗方式。
 
 Several studies have explored potential HAIC-based combination strategies (Table 2).
一些研究已经探索了潜在的基于HAIC的组合策略(表)。


文献 研究设计 病例数 方案 CP-B(%) HBV(%) PVT(%) EHS(%) ORR(%) OS(月) P值
INFα Sakon et al. [42]
Phase 2
single arm
VP3–4, no EHS
11 5-FU 450–500 mg/m2,
Days 1–5
INF-α5 MU qW1,3,5
54.5 36.4 100 0 72.7 8.0  
Eun et al. [43] Retrospective
single arm
31 HAIC: 5-FU 750 mg/m2,
cisplatin 25 mg/m2, Days 1–4
19.4 83.9 100 NR 19.4 4.0 0.353
21 INF-α 3MU Days 1–4, then QOD HAIC alone: 5-FU 750 mg/m2,
cisplatin 25 mg/m2, Days 1–4
19.0 85.7 100 NR 42.9 7.0
索拉非尼 Ikeda et al. [44] Randomized
Phase 2
CPS-A, B7
65 Cisplatin 65 mg/m2, Day 1
Every 4–6 weeks
plus sorafenib
12.3 33.8 61.5 29.2 21.7 10.8 0.031
41 索拉非尼 4.9 22.0 41.5 31.7 7.3 8.7
Kudo et al. [45
顶一下
(0)
0%
踩一下
(0)
0%
------分隔线----------------------------
  • 上一篇:没有了
  • 下一篇:没有了
推荐内容